This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Rectal Cancer or Prognosis
and you are
between 18 and 80
years old
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

We explored the relationship between NLR and grade 3 or higher treatment related small bowel toxicity and treatment outcome of patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy (IMRT).

Provided treatments

  • Radiation: capecitabine and concurrent intensity modulated radiotherapy

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03015168. The sponsor of the trial is General Hospital of Ningxia Medical University and it is looking for 117 volunteers for the current phase.
Official trial title:
Prognostic Value of Neutrophil-to-lymphocyte Ratio (NLR) on Rectal Cancer Patients Who Received Capecitabine and Concurrent Intensity Modulated Radiotherapy (IMRT)